Comparative Pharmacology
Head-to-head clinical analysis: VIVJOA versus XELJANZ XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIVJOA versus XELJANZ XR.
VIVJOA vs XELJANZ XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIVJOA (fosmanogepix) is a first-in-class antifungal agent that inhibits the fungal enzyme Gwt1, which is involved in glycosylphosphatidylinositol (GPI) anchor biosynthesis. This disrupts cell wall integrity and fungal growth.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and TYK2, modulating cytokine signaling pathways involved in immune responses.
VIVJOA (750 mg tablet) is administered as a single oral dose of 750 mg, taken once daily for 6 weeks.
11 mg orally once daily, with or without food, for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; for ulcerative colitis, use 5 mg twice daily if switching from immediate-release tofacitinib 5 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20–26 hours, supporting once-daily dosing for sustained therapeutic levels.
Terminal elimination half-life is approximately 3.3 hours for the immediate-release formulation; for XELJANZ XR (extended-release), effective half-life is prolonged due to extended absorption, but terminal half-life remains ~3.3 hours. Clinical context: Twice-daily dosing for IR, once-daily for XR.
Primarily hepatic metabolism via CYP3A4, with <1% excreted unchanged in urine; fecal elimination accounts for approximately 88% of the administered dose as metabolites.
Renal excretion accounts for approximately 70% of total clearance (30% unchanged drug, 40% as metabolites); biliary/fecal excretion accounts for approximately 30% of total clearance (metabolites).
Category C
Category C
JAK Inhibitor
JAK Inhibitor